Patient characteristics
| . | TI patients with NDMM (N = 360) . | TI patients with NDMM treated with Len∗ (n = 174) . | With SyM (n = 16) . | With SPM (n = 12) . |
|---|---|---|---|---|
| Age, median (min-max), y | ||||
| At diagnosis of MM | 80 (70-103) | 78 (70-92) | 80 (72-89) | 74 (70-85) |
| At diagnosis of AdM | 80 (72-89) | 78 (72-87) | ||
| Gender ratio† (male-to-female) | 1.3 (205/155) | 1.2 (94/80) | 3 (12/4) | 1.4 (7/5) |
| Personal history, n (%) | ||||
| Previous cancer | 71 (20) | 30 (17) | 4 (25) | 1 (8) |
| Previous radiotherapy | 31 (9) | 16 (9) | 0 | 0 |
| Previous chemotherapy | 8 (2) | 4 (2) | 0 | 0 |
| Subtypes of myeloma | ||||
| Smoldering MM | 66 (18) | 2 (1) | 4 (25) | |
| Active MM | 291 (81) | 172 (99) | 12 (75) | 12 (100) |
| Plasmacytoma | 3 (1) | |||
| ISS‡ | ||||
| I | 47 (16) | 36 (21) | 1 (8) | 5 (41) |
| II | 80 (28) | 54 (31) | 3 (25) | 2 (17) |
| III | 91 (31) | 49 (29) | 4 (33) | 3 (25) |
| Unknown | 73 (25) | 33 (19) | 4 (33) | 2 (17) |
| Treatment combinations | ||||
| No treatment | 61 (17) | 0 | 4 (25) | 0 |
| With chemotherapy | 52 (14) | 0 | 3 (19) | 0 |
| Without Len | 68 (19) | 0 | 6 (38) | 0 |
| Len alone ± dex | 45 (13) | 43 (25) | 2 (12) | 2 (17) |
| Len with anti-CD38 | 22 (6) | 22 (12) | 0 | 0 |
| Len with PI | 102 (28) | 99 (57) | 1 (6) | 10 (83) |
| Len + anti-CD38 + PI | 10 (3) | 10 (6) | 0 | 0 |
| . | TI patients with NDMM (N = 360) . | TI patients with NDMM treated with Len∗ (n = 174) . | With SyM (n = 16) . | With SPM (n = 12) . |
|---|---|---|---|---|
| Age, median (min-max), y | ||||
| At diagnosis of MM | 80 (70-103) | 78 (70-92) | 80 (72-89) | 74 (70-85) |
| At diagnosis of AdM | 80 (72-89) | 78 (72-87) | ||
| Gender ratio† (male-to-female) | 1.3 (205/155) | 1.2 (94/80) | 3 (12/4) | 1.4 (7/5) |
| Personal history, n (%) | ||||
| Previous cancer | 71 (20) | 30 (17) | 4 (25) | 1 (8) |
| Previous radiotherapy | 31 (9) | 16 (9) | 0 | 0 |
| Previous chemotherapy | 8 (2) | 4 (2) | 0 | 0 |
| Subtypes of myeloma | ||||
| Smoldering MM | 66 (18) | 2 (1) | 4 (25) | |
| Active MM | 291 (81) | 172 (99) | 12 (75) | 12 (100) |
| Plasmacytoma | 3 (1) | |||
| ISS‡ | ||||
| I | 47 (16) | 36 (21) | 1 (8) | 5 (41) |
| II | 80 (28) | 54 (31) | 3 (25) | 2 (17) |
| III | 91 (31) | 49 (29) | 4 (33) | 3 (25) |
| Unknown | 73 (25) | 33 (19) | 4 (33) | 2 (17) |
| Treatment combinations | ||||
| No treatment | 61 (17) | 0 | 4 (25) | 0 |
| With chemotherapy | 52 (14) | 0 | 3 (19) | 0 |
| Without Len | 68 (19) | 0 | 6 (38) | 0 |
| Len alone ± dex | 45 (13) | 43 (25) | 2 (12) | 2 (17) |
| Len with anti-CD38 | 22 (6) | 22 (12) | 0 | 0 |
| Len with PI | 102 (28) | 99 (57) | 1 (6) | 10 (83) |
| Len + anti-CD38 + PI | 10 (3) | 10 (6) | 0 | 0 |